الفهرس 
CancerOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
CHAPTER: VI English Summary Cancer is a class of disease characterized by uncontrolled cell division and the ability of these cells to invade other tissue, either by direct growth into adjacent tissue (invasion) or by migration of cells to
distant sites (metastasis). This unregulated growth is caused by a series
of acquired or inherited mutations of DNA within cells, damaging
genetic information that define the cell function and removing normal
control of cell division, it is well known that cancer is a very dangerous
disease which eventually leads to the death.
Scientists direct their effort to cancer therapy. Chemotherapy,
radiotherapy hormonal therapy are representatives of cancer treatment but
all these have many side effect on the human body and can not
discriminate between the normal and cancer cells. Recently the scientists
all over the world directed their effort to use natural products as therapeutic
drugs for many diseases which cancer is one of them; because of their
effectiveness towards cancer treatment with low side effects and powerful
ability to distinguish between normal and cancer cells.
Lectin is a natural product found principally in plants especially
Legumes and also in some invertebrate which grows on the branches of
decided trees, chiefly apple, poplar and plum.
The present study amid to evaluate the antitumor activity of lectin
against mice bearing solid tumor subcutaneously implemented with
Ehrlich Ascites carcinoma (EAC) cells.
The experimental mice were classified into the following groups:
1-Normal control mice group received saline solution.
PDF created with pdfFactory Pro trial version www.pdffactory.com
English Summary_______________________________________________________
______________________________ _________________________________ 85
2-Mice-bearing solid tumor untreated and received saline solution (positive
control mice group).
3-Mice-bearing solid tumor treated with lectin at different concentrations
(650,750,850 ng/100 g body weight).
The results showed that:
1- Lectin at dose of (650 ng/100 g body weight) significantly decrease
tumor volume from (2.068+0.15) mm3 to (1.032+0.19) mm3, while
lectin at dose of (750 ng/100 g body weight) significantly decrease
the same volume to (1.624+0.94) mm3 and lectin at dose of (850
ng/100 g body weight) significantly decrease it to (1.838+0.044) mm3
respectively . This means that Lectin has antitumor activity that can
regress tumor growth and at (650 ng/100 g body weight) doses is
effective than other doses used .
2- Positive control animal group implemented with (EAC) exhibited
a highly significant increase in IL-12 level (3.985+0.586) compared
to normal control group (2.485+0.502). Lectin treated group at dose
of (650ng/100 g body weight) showed a significant decrease in IL-12
level (2.545+0.565) compared to lectin treated group at dose 0f
(750ng/100 g body weight) was(2.753+0.588) and lectin treated
group at dose 0f (850ng/100 g body weight) was (2.655+0.573)
respectively. At the mean time lectin treated group at dose 0f
(850ng/100 g body weight) (2.655+0.573) exhibited a significant
increase compared to lectin treated group at dose 0f (750ng/100 g body
weight) (2.753+0.588).
PDF created with pdfFactory Pro trial version www.pdffactory.com
English Summary_______________________________________________________
______________________________ _________________________________ 86
3- Positive control animal group implemented with (EAC) exhibited a
highly significant decrease in T.N.F level (3.308+0.602) compared to
normal control group (5.307+1.303).Lectin treated group at dose of
(650ng/100 g body weight) showed a significant increase in TNF
level (5.166+1.503) compared to lectin treated group at dose 0f
(750ng/100 g body weight) (4.456+1.045) and lectin treated group at
dose 0f (850ng) (4.756+0.506) respectively. At the mean time lectin
treated group at dose 0f (850ng) (4.756+0.506) exhibited a significant
increase compared to lectin treated group at dose 0f (750ng)
(4.456+1.045)
4- Liver histopathology of mice bearing Ehrlich ascites carcinoma cells
treated with Lectin (650 ng /100 g body weight) showed normal
central vein, normal hepatic lobules and enlarged blood sinusoids
compared to control group.
5- Kidney histopathology in mice bearing Ehrlich ascites carcinoma
cells treated with lectin (650ng /100 g body weight) showed dilated
blood vessels and normal glomeruli with normal subcapsular space
compared to control group.
PDF created with pdfFactory Pro trial version www.pdffactory.com
English Summary_______________________________________________________
______________________________ _________________________________ 87
Short Summary
The present study amid to evaluate the antitumor activity of lectin against
mice bearing solid tumor subcutaneously implemented with Ehrlich
Ascites carcinoma (EAC) cells.
The experimental mice were classified into the following
groups:
1-Normal control mice group received saline solution.
2-Mice-bearing solid tumor untreated and received saline solution (positive
control mice group).
3-Mice-bearing solid tumor treated with lectin at different concentrations
(650,750,850 ng/100 g body weight).
The results showed that:
1- Lectin at dose of (650 ng/100 g body weight) significantly decrease
tumor volume from (2.068+0.15) mm3 to (1.032+0.19) mm3, while
lectin at dose of (750 ng/100 g body weight) significantly decrease
the same volume to (1.624+0.94) mm3 and lectin at dose of (850
ng/100 g body weight) significantly decrease it to (1.838+0.044) mm3
respectively . This means that Lectin has antitumor activity that can
regress tumor growth and at (650 ng/100 g body weight) doses is
effective than other doses used .
PDF created with pdfFactory Pro trial version www.pdffactory.com
English Summary_______________________________________________________
______________________________ _________________________________ 88
2- Positive control animal group implemented with (EAC) exhibited
a highly significant increase in IL-12 level (3.985+0.586) compared
to normal control group (2.485+0.502). Lectin treated group at dose
of (650ng/100 g body weight) showed a significant decrease in IL-12
level (2.545+0.565) compared to lectin treated group at dose 0f
(750ng/100 g body weight) was(2.753+0.588) and lectin treated
group at dose 0f (850ng/100 g body weight) was (2.655+0.573)
respectively. At the mean time lectin treated group at dose 0f
(850ng/100 g body weight) (2.655+0.573) exhibited a significant
increase compared to lectin treated group at dose 0f (750ng/100 g body
weight) (2.753+0.588).
3- Positive control animal group implemented with (EAC) exhibited a
highly significant decrease in T.N.F level (3.308+0.602) compared to
normal control group (5.307+1.303).Lectin treated group at dose of
(650ng/100 g body weight) showed a significant increase in TNF
level (5.166+1.503) compared to lectin treated group at dose 0f
(750ng/100 g body weight) (4.456+1.045) and lectin treated group at
dose 0f (850ng) (4.756+0.506) respectively. At the mean time lectin
treated group at dose 0f (850ng) (4.756+0.506) exhibited a significant
increase compared to lectin treated group at dose 0f (750ng)
(4.456+1.045)
4- Liver histopathology of mice bearing Ehrlich ascites carcinoma cells
treated with Lectin (650 ng /100 g body weight) showed normal
central vein, normal hepatic lobules and enlarged blood sinusoids
compared to control group.
5- Kidney histopathology in mice bearing Ehrlich ascites carcinoma
cells treated with lectin (650ng /100 g body weight) showed dilated
PDF created with pdfFactory Pro trial version www.pdffactory.com
English Summary_______________________________________________________
______________________________ _________________________________ 89
blood vessels and normal glomeruli with normal subcapsular space
compared to control group.